Sortilin is associated with progranulin deficiency and autism‐like behaviors in valproic acid‐induced autism rats
CNS Neuroscience & Therapeutics · 2024-09 · 30 (9)
DOI: 10.1111/cns.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024-09. Verfasst von Ailing Liao und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chon…. Hauptthemen laut MEDLINE: Adaptor Proteins, Vesicular Transport, Autistic Disorder, Progranulins, Valproic Acid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing, China, Science and technology research program of Chongqing Education Commission of China., the Chongqing Children's Aid Foundation (Life and Social Interaction Enhancement Program for Children with Autism.
Abstract (Originalsprache)
Introduction
Neuroinflammation and microglial activation‐related dendritic injury contribute to the pathogenesis of Autism Spectrum Disorder (ASD). Previous studies show that Progranulin (PGRN) is a growth factor associated with inflammation and synaptic development, but the role of PGRN in autism and the mechanisms underlying changes in PGRN expression remain unclear.
Aims
To investigate the impact of PGRN in autism, we stereotactically injected recombinant PGRN into the hippocampus of ASD model rats. Additionally, we explored the possibility that sortilin may be the factor behind the alterations in PGRN by utilizing SORT1 knockdown. Ultimately, we aimed to identify potential targets for the treatment of autism.
Results
PGRN could alleviate inflammatory responses, protect neuronal dendritic spines, and ameliorate autism‐like behaviors. Meanwhile, elevated expression of sortilin and decreased levels of PGRN were observed in both ASD patients and rats. Enhanced sortilin levels facilitated PGRN internalization into lysosomes. Notably, suppressing SORT1 expression amplified PGRN levels, lessened microglial activation, and mitigated inflammation, thereby alleviating autism‐like behaviors.
Conclusion
Collectively, our findings highlight elevated sortilin levels in ASD rat brains, exacerbating dendrite impairment by affecting PGRN expression. PGRN supplementation and SORT1 knockdown hold potential as therapeutic strategies for ASD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, China.
- Institute of Neuroscience, School of Basic Medical Science, Chongqing Medical University, Chongqing, China.
- Library/Archive, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Ailing Liao
Förderung
- Natural Science Foundation of Chongqing, China
- Science and technology research program of Chongqing Education Commission of China.
- the Chongqing Children's Aid Foundation (Life and Social Interaction Enhancement Program for Children with Autism
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Liao, A., Zheng, W., Wang, S., Wang, N., Li, Y., Chen, D., & Wang, Y. (2024). Sortilin is associated with progranulin deficiency and autism‐like behaviors in valproic acid‐induced autism rats. CNS Neuroscience & Therapeutics, 30(9). https://doi.org/10.1111/cns.70015
Vancouver
Liao A, Zheng W, Wang S, Wang N, Li Y, Chen D, et al. Sortilin is associated with progranulin deficiency and autism‐like behaviors in valproic acid‐induced autism rats. CNS Neuroscience & Therapeutics. 2024;30(9). doi:10.1111/cns.70015
BibTeX
@article{Liao2024,
author = {Liao, Ailing and Zheng, Wenxia and Wang, Shali and Wang, Nashi and Li, Yingbo and Chen, Di and Wang, Yan},
title = {Sortilin is associated with progranulin deficiency and autism‐like behaviors in valproic acid‐induced autism rats},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {9},
doi = {10.1111/cns.70015}
}
EUVIMED